{"entity":{"id":"gritstone","kind":"company","name":"Gritstone bio","aka":[],"tldr":"Neoantigen-vaccine pioneer (GRANITE, SLATE) that ran out of money and filed for bankruptcy in October 2024; a cautionary tale for the personalised-vaccine field.","summary":"Gritstone's GRANITE individualised neoantigen vaccine (adenoviral prime, samRNA boost) showed a molecular-response signal in a phase 2/3 colorectal cancer maintenance trial but not enough to fund completion. Chapter 11 filing 10 October 2024; assets sold at auction (Seattle Project Corp. and others) for about $21M in December 2024.","status":"withdrawn","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Gritstone_bio","links":[{"label":"Bankruptcy and asset sale","url":"https://www.nasdaq.com/articles/gritstone-bio-files-bankruptcy-and-auctions-assets"}],"tags":["failure"],"related":[],"cancers":["colorectal"],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine","shared-antigen-vaccine"],"targets":[],"drugs":["grt-c901","grt-r902"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Emeryville, CA","country":"US","companyType":"biotech","website":"https://www.gritstonebio.com","investors":[],"funding":[]},"route":"/companies/gritstone/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"drug":[{"id":"grt-c901","kind":"drug","name":"GRT-C901","route":"/drugs/grt-c901/"},{"id":"grt-r902","kind":"drug","name":"GRT-R902","route":"/drugs/grt-r902/"}]}}